• Who we are
    • ABOUT MEDICINES FOR EUROPE
    • PURPOSE AND OBJECTIVES
    • OUR VALUES – OUR 5 PILLARS
    • STRUCTURE
    • MEMBERS
    • BECOME A MEMBER
    • CODE OF CONDUCT
    • DISCLOSURE
  • Key topics
    • COVID-19
    • ACCESS
    • INDUSTRIAL POLICY
    • REGULATORY AND LEGAL FRAMEWORK
    • FALSIFIED MEDICINES
    • ENVIRONMENT
    • ANTIMICROBIAL RESISTANCE
    • MEDICINE SHORTAGES
  • Publications
    • EXTERNAL RESOURCES
    • FACTSHEETS
    • INFOGRAPHICS
    • PODCAST
    • POLICY
    • REPORTS
    • VIDEOS
  • Newsroom
    • IN THE NEWS
    • PRESS RELEASES
  • Contact us
Login Login
Medicines for Europe
  • Generic medicines
    • Home
    • Medicines for Europe
      • Generic medicines Group
      • MISSION AND VISION
      • STRUCTURE
      • MEMBERS
      • BECOME A MEMBER
    • Did you know?
      • Definition
      • THERAPEUTIC AREAS
      • GLOSSARY
      • Q&A
    • What’s new
      • FACTSHEETS
      • POLICY
      • REPORTS
      • VIDEOS
      • INFOGRAPHICS
    • Our 5 pillars
      • Patients
      • QUALITY
      • VALUE
      • SUSTAINABILITY
      • PARTNERSHIP
    • Find out more
      • Related links
      • Contact us
    • Twitter
  • Biosimilar medicines
    • Home
    • Medicines for Europe
      • Biosimilar medicines Group
      • MISSION AND VISION
      • STRUCTURE
      • MEMBERS
      • BECOME A MEMBER
    • Did you know?
      • DEFINITION
      • THERAPEUTIC AREAS
      • GLOSSARY
      • Q&A
    • What’s new
      • FACTSHEETS
      • POLICY
      • REPORTS
      • VIDEOS
      • INFOGRAPHICS
      • External resources
    • Our 5 pillars
      • Patients
      • QUALITY
      • VALUE
      • SUSTAINABILITY
      • PARTNERSHIP
    • Find out more
      • Related links
      • Contact us
    • Twitter
  • Value added medicines
    • Home
    • Who we are
      • Value added medicines Group
      • MISSION AND VISION
      • STRUCTURE
      • MEMBERS
      • BECOME A MEMBER
    • Did you know?
      • Definition
      • THERAPEUTIC AREAS
      • Q&A
    • What’s new
      • FACTSHEETS
      • POLICY
      • REPORTS
      • VIDEOS
      • INFOGRAPHICS
    • Our 5 pillars
      • Patients
      • QUALITY
      • VALUE
      • SUSTAINABILITY
      • PARTNERSHIP
    • Find out more
      • Contact us
  • Events

Find out more

Related links

EC Consensus Document: http://ec.europa.eu/DocsRoom/documents/8242

EMA: http://www.ema.europa.eu/ema/index.jsp?curl=pages/special_topics/document_listing/document_listing_000318.jsp

European Commission DG SANTE: http://ec.europa.eu/dgs/health_food-safety/

European Commission DG GROWTH: http://ec.europa.eu/growth/

US Food and Drug Administration: http://www.fda.gov/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/ApprovalApplications/TherapeuticBiologicApplications/Biosimilars/

WHO Expert Committee on Biological Standarization (ECBS): http://www.who.int/biologicals/WHO_ECBS/en/

IGBA website: http://www.igbamedicines.org

PLOS: https://www.plos.org/open-access

PubMed: http://www.ncbi.nlm.nih.gov/pubmed

Medicines for Europe
MEMBER OF
IGBA EMVO
  • Contact us
  • Privacy Policy
Medicines for Europe AISBL
Rue d’Arlon 50
1000 Brussels Belgium
T : +32 (0)2 736 84 11
Powered by Big Smile Agency
Medicines For Europe
  • Who we are
  • Key topics
  • Publications
  • Newsroom
  • Contact us
  • SECTOR GROUPS
    • Generic medicines
      • WHO WE ARE
      • DID YOU KNOW?
      • WHAT’S NEW
      • OUR 5 PILLARS
      • FIND OUT MORE
    • Biosimilar medicines
      • WHO WE ARE
      • DID YOU KNOW?
      • WHAT’S NEW
      • OUR 5 PILLARS
      • FIND OUT MORE
    • Value added medicines
      • WHO WE ARE
      • DID YOU KNOW?
      • WHAT’S NEW
      • OUR 5 PILLARS
  • Events
 Tweet
 Tweet
 Tweet
 LinkedIn